Today's Rundown Featured Story | | | Wednesday, April 3, 2019 Sorrento Therapeutics alleged Patrick Soon-Shiong and one of his companies bought Sorrento's late-phase cancer drug Cynviloq to hamstring its development and prevent the drug from reaching the market in which it would compete with Abraxane, a drug Soon-Shiong invented and sold to Celgene back in 2010. |
|
|
Top Stories Thursday, April 4, 2019 Daiichi Sankyo's PDUFA date for its FLT3 inhibitor has been pushed back to late August. The FDA wants more time to go over new data from the Japanese pharma. Thursday, April 4, 2019 Just a week out from the European liver disease conference in Vienna, where you can expect much of the hype to be around nonalcoholic steatohepatitis drugs, fatty liver disease biotech NGM Biopharmaceuticals has got off a $107 million IPO, following in the footsteps of rival GenFit. Monday, April 1, 2019 Deloitte discusses how biotech companies are exploring alternative strategies to fund growth including IPOs, collaborative arrangements, and share-based payment arrangements. Thursday, April 4, 2019 Cytovant starts out with the Asian rights to two Medigene programs—a T-cell receptor treatment and a dendritic cell vaccine—and a partnership to develop two more TCR programs. Wednesday, April 3, 2019 The brain's microglia scout around the brain for debris such as damaged neurons and protein plaques. A Stanford University team has discovered that CD22 prevents this important function and tuning it down improves cognitive function in aged mice. Resources Sponsored by: Data MATRIX | 3:00 AM EDT / 9:00 AM EDT / 2:00 PM EDT How to cut a study budget by 4 times? How to process CRFs 3 times faster? What made a CRO switch from a US vendor to Data MATRIX? In 45 minutes, we will dissolve myths about entering the market. Sponsored by: USDM Life Sciences The year’s biggest compliance and technology trends in life sciences. Learn about the latest trends impacting the biotech, medical device and pharmaceutical industries. Sponsored by: Eurofins Discovery Learn how to utilize allosteric modulation to maximize its full potential in drug discovery programs. Download this white paper to learn more. Sponsored by: BioAnalytix, Inc. Discussion of the potential for improving biologic drug development success through earlier, strategic application of advanced mass spectrometry, because currently, with most biologic drugs, including gene therapies, failures are realized in late-stage development, after substantial investment has been made in a candidate. Sponsored by: PointCross Life Sciences Clinical trials and biomarker data from patients when unified, harmonized, and made searchable; is a rich, reliable and controlled resource for research. This paper sets out the requirements for a Translational and Biomarker Research Workbench for scientists using the experiences from use of Xbiom™ at BioPharma. Sponsored by: Unchained Labs Download this whitepaper to learn more! Sponsored by: Patheon, part of Thermo Fisher Scientific Is Flow Chemistry right for your API Development? Sponsored by: Veradigm Real-World case study by Veradigm suggests that new medications specifically approved for the treatment of systolic heart failure may be underutilized despite being important advances in patient care. Sponsored by: Outer Edge Technology Software end of life puts you at risk for data breaches, business disruption and liability. Support for Microsoft SQL Server 2008/2008 R2 and Windows Server 2008/2008 R2 ends on July 9, 2019 and January 14, 2020, respectively. Learn how you can turn these risks into a strategic business advantage. Sponsored by: AlphaSense From new regulations to drug pricing and the latest M&A deals, learn how AI is making it easier for competitive intelligence to uncover the insights they need to stay ahead of the curve. Sponsored by: InterSystems Analytics using patients’ real-time longitudinal laboratory results, and claims data, yielded higher value information and new revenue streams for TriCore reference laboratories. Sponsored by: InterSystems Whitepaper on leveraging normalized real-world patient data to streamline clinical trials, reduce delays and lower costs. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. | 
